BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP
C21 Investments Inc. CXXIF
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$32.6M
▲ 8.3% vs FY2024
EPS · FY25
$-0.03
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-12.0%
Net margin · FY25
-9.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 32.6M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 10 cents on every revenue dollar this year.
Per share
USD -0.03
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-12.0%
Return on equity, FY2025
ROE
Operating margin7.0%
Net margin-9.9%
Return on assets-5.8%
Each USD of equity lost 12 cents this year.
Returned to shareholders
USD 103,034.00
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 103,034.00
Share of profit-3.2%
Consecutive raises—
USD 103,034.00 in buybacks went back to shareholders in a year without profit.
Growth
−0.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+4.1%
−0.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.12B
Shares outstanding, FY2025
Change, 5 years+0.7%
Change, 10 years—
The share count grew 1% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 54.4M
total assets, end of FY2025
Total assetsUSD 54.4M
EquityUSD 25.4M
Current ratio1.30×
Equity funds 47% of total assets.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
0.0
0.0
−0.0
EPS, diluted $
−0.03
−0.03
−0.03
0.00
0.08
−0.07
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−12.0
−13.3
−10.1
0.9
34.9
−33.7
Shares out B
0.12
0.12
0.12
0.12
0.12
0.12
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
23 of 23
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed